Insomnia

...ba href=/insomnia/a/b; Phase II expected to start in H2 2006 - EVT 301, a Phase I compound with the potential to reduce symptoms progression in Alzheimer's disease in-licensed from Roche; on track to enter Phase II at the end of 2006 - Phase I study for Alzheimer's disease compound EVT 101 initiated, Single Ascending Dose Study (SAD) completed with positive results Reinforced customer relations successfully: - Already sizeable programme with Boehringer Ingelheim doubled and extended to the end of 2008; two milestones achieved in May 2005 and in March 2006 - Strategic collaboration with Roche extended and expanded - Strong performance in chemical and pharmaceutical development services: - Three customer compounds in development for commercial manufacture - Strong sales in formulation business, now fully integrated into Evotec's service offering - First milestone in Alzheimer's disease collaboration with Takeda Financials: - Group revenues increased by 10% to EUR 79.8 m (2004: EUR 72.7 m); Q4 revenues up 5% to EUR 26.5 m (2004: EUR 25.3 m) - Strong performance in Services Division, exceeding expectations: - Revenues up 12% to EUR 61.0 m (2004: EUR 54.5 m) - Operating result excluding amortisation charges positive at EUR 1.5 m (2004: EUR (9.9) m) - Group operating result improved by 58%; operating result before amortisation and impairment improved by 31% to EUR (8.1) m in line with increased gross profit - Acquisition of full ownership interest in Evotec Neurosciences and PIPE in May/June 20...

...ba href=/insomnia/a/b drug made by Sepracor.

And there are more on the way that he says are worth watching.

The two key drug launches this year are of Sutent, Pfizer's first big entry into cancer drugs, and Acomplia, the anti-obesity pill being developed by Sanofi-Aventis.

Sutent is already on the market, although sales data are not yet available.

Acomplia has been delayed at the U.S.

Food and Drug Administration and rejected as a stop-smoking drug.

Some cardiologists, who are excited about the drug because of its potential to reduce the risk of heart disease, are also worried about side effects.

Acomplia works by blocking the same brain receptor that makes pot smokers hungry; psychiatric symptoms like anxiety are one of the most common reasons patients stopped taking Acomplia in clinical trials.

"It's a pill that blocks the 'happy receptor,' " says Prediman K.

Shah of Cedars Sinai Medical Center.

"The main reason for concern is that it might have an adverse impact on depression or suicide." He is nonetheless very excited about the pill.

Click here for a slide show of the top 10 best-selling drugs.

  Page 1 of 1    refresh all collapse all Rants & Raves Start a new thread or reply to a post below.  Logout  Want to start a new thread or reply to a post?

  Login / Register and start talking!

  Post   Cancel Note: You are reading this message either because you can not see our css files, or because you do not have a standards-compliant browser.

Read our design not...

...ba href=/insomnia/a/b, and I think I may have found a cure - listening to Dave Heineman.

Tom Osborne didn't have a very impressive performance either.

Although I must give him credit, because he held off mentioning the Cornhuskers until the very end of the debate.

Osborne also lacked enthusiasm, which made me wonder how he was ever a football coach.

I guess talking about Nebraska is just that depressing.

Finally, we get to Dave Nabity.

What Osborne and Heineman lacked in enthusiasm and passion, Nabity made up for.

Unfortunately, when Nabity opened his mouth, some of the sentences and ideas strewn together just didn't add up.

Nabity did provide the most interesting answer in the debate.

When I say interesting, I mean idiotic.

Nabity was asked how Nebraska should deal with its methamphetamine problem.

Nabity responded by saying citizens that turn-in meth users are fearful because the meth user can post bail and track the snitch down.

He continued his answer by saying, "I don't think we're going to be able to get the citizens to step up and get active at trying to catch these people unless they can conceal and carry weapons.

I think it's very important that we change the gun laws so that we have the citizens step up and start helping law enforcement so we can start finding these people and putting them away." That answer was idiotic on two different levels - probably more.

It's the most idiotic justification for conceal and carry I've ever heard, and it was the stupidest solution to the drug...